Quantcast

Latest treatment of migraine Stories

2014-03-27 08:34:36

AVP-825 relies on novel closed palate Breath Powered(TM) drug delivery technology YARDLEY, Pa., March 27, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for AVP-825, an innovative closed-palate Breath Powered(TM) investigational drug-device combination product for the acute treatment of migraine. As previously reported, the 505(b)(2) NDA for AVP-825 includes clinical data developed by OptiNose including a pivotal phase...

2014-03-26 08:30:13

ALISO VIEJO, Calif., March 26, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) of AVP-825, its innovative Breath Powered(TM) investigational drug-device combination product for the acute treatment of migraine. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO As previously reported the company's 505(b)(2) NDA for AVP-825 includes data from...

2014-01-30 08:32:03

ALISO VIEJO, Calif., Jan. 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of AVP-825, its innovative Breath Powered(TM) investigational drug-device combination product for the acute treatment of migraine. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) The company's 505(b)(2) NDA for AVP-825 includes data from one...

2014-01-22 12:26:19

New Guidelines Support Use by Migraine Specialists in the UK SUNNYVALE, Calif., Jan. 22, 2014 /PRNewswire/ -- eNeura Inc., a privately held medical technology company, announced today that the United Kingdom's National Institute for Health and Care Excellence (NICE) has published interventional procedure guidance recommending Transcranial Magnetic Stimulation (TMS) for the treatment of migraine. The new guidelines are based on a thorough technology appraisal, which includes...

2014-01-08 08:28:02

SAN MATEO, Calif., Jan. 8, 2014 /PRNewswire/ -- Labrys Biologics Inc., a biotechnology company focused on treatments for migraine, today announced that patients are now being enrolled in two separate Phase 2b clinical studies of LBR-101 (formerly RN-307) as a subcutaneous once-monthly treatment for the prevention of frequent migraines. The first study is enrolling subjects with chronic migraine, who experience at least 15 headache days per month. The second study is enrolling subjects...

2011-08-11 06:05:00

MOUNTAIN VIEW, Calif., Aug. 11, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Patent and Trademark Office (USPTO) issued to the Company U.S. Patent No. 7,994,197, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile." The patent, which expires in 2028, results from the Company's discovery that dihydroergotamine (DHE) can be administered to achieve pharmacokinetic...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.